Rapid Communication

Expression of altered retinoblastoma protein inversely correlates with tumor invasion in gastric carcinoma

Nan-Hua Chou, Hui-Chun Chen, Nan-Song Chou, Ping-I Hsu, Hui-Hwa Tseng

AIM: To investigate the clinical and pathological significance of altered retinoblastoma (Rb) encoding protein (pRb) in gastric carcinoma.

METHODS: Expression of altered pRb was analyzed in 91 patients with gastric adenocarcinoma by immunohistochemistry.

RESULTS: Sixty-five percent (59/91) of the tumors were positively stained and the staining in tumor nuclei of gastric carcinoma ranged 0%-90%. Moreover, strong expression of altered pRb was found in 35% (6/17), 24% (5/21), 17% (8/46) and 0% (0/7) of T1, T2, T3 and T4 gastric carcinomas, respectively. Advanced pRb expression was inversely correlated with the depth of tumor invasion (P = 0.047). Degree of immunoreactivity had no significant correlation with tumor grade, node metastasis and distant metastasis. In terms of prognostic significance, univariate analysis showed that poor differentiation [41 (66.1%) vs 34 (42.5%) P = 0.051], advanced tumor stage (P < 0.001) and weakly altered pRb expression [17 (80.5%) vs 58 (49.6%) P = 0.044] were associated with worse prognosis in these patients. However, multivariate analysis revealed that advanced tumor stage was the only independent poor prognostic factor (P < 0.001).

CONCLUSION: The mutation of Rb gene is frequent in gastric carcinoma. The expression of altered pRb inversely correlates with tumor invasion and is not an independent prognostic marker in gastric adenocarcinoma.

Key words: Gastric adenocarcinoma; Altered retinoblastoma protein; Immunohistochemistry

Chou NH, Chen HC, Chou NS, Hsu PI, Tseng HH. Expression of altered retinoblastoma protein inversely correlates with tumor invasion in gastric carcinoma. World J Gastroenterol 2006; 12(44): 7188-7191

http://www.wjgnet.com/1007-9327/12/7188.asp

INTRODUCTION

Cellular proliferation normally follows an orderly progression through the cell cycle, which is governed by protein complexes encoding various genes. Malignant transformation results from a series of genetic alterations that lead to aberrant regulation of cell division (cell-cycle control), cell death (apoptosis), and maintenance of genomic integrity (DNA repair).

The retinoblastoma gene (Rb) encoding the 105kd nuclear phosphoprotein, maps to chromosome 13, band 13q14, and is a prototypical tumor-suppressor gene[1-2]. The retinoblastoma protein plays an important role in regulating the ability of cells to enter S phase, during which DNA is synthesized[3]. Although the alteration of the Rb gene has been shown to be critical for the development of retinoblastoma[4-6], dysregulation of the Rb gene is important in a wide array of human cancers, such as sarcoma[7], hepatoma[8], leukemia[9], breast[10], bladder[11], prostate[12] and lung cancers[13]. But studies concerning Rb gene change in gastric carcinoma are limited.

This study was to examine the correlation of altered pRb expression with the clinicopathological status and prognostic value of altered protein expression in patients with gastric carcinoma.

MATERIALS AND METHODS

Patients

The study population consisted of 91 patients (80 men, 11 women; mean age: 68 years; range: 32-86 years) who underwent surgery for primary gastric adenocarcinoma at our institute between 1992 and 2000. Eighteen (19.8%) tumors were located in the upper third, 19 (20.9%) in the middle third, and 54 (59.3%) in the lower third of the stomach, respectively. Following the international tumor node metastasis (TNM) staging system, 23 (25.3%)
tumors were considered stage I, 20 (22.0%) stage II, 28 (30.8%) stage III, and 20 (22.0%) stage IV, respectively. Histological grade was assessed following the World Health Organization (WHO) criteria. Forty-nine (53.8%) tumors were well- or moderately-differentiated, and forty-two (46.2%) poorly- or undifferentiated.

Sixteen of the 20 stage IV patients had distant metastasis (5 peritoneal, 5 hepatic, 1 lung, 3 peritoneal and T4 lesion, 1 peritoneal and hepatic, 1 peritoneal and N3 lymph node status), while the other cases were classified as stage IV because of N3 lymph node status (n = 3) and/or T4 lesions (n = 1). Sixteen patients underwent palliative surgery (16 distant metastases). The other 75 patients underwent radical D2 resection. Of the patients 12 were treated with postoperative systemic chemotherapy (5 for 6 cycles of FEM, and 7 for 6 cycles of 5-FU). To rule out any confounding effect of adjuvant chemotherapy, this variable was entered in the multivariate analysis of survival. Follow-up evaluation consisted of physical examination, chest radiography, and tumor marker (CEA, and CA19.9) assay every 6 mo for the first 3 years and once a year thereafter, abdominal computed tomography (CT), and endoscopy once a year.

**Immunohistochemistry**

Formalin-fixed and paraffin-embedded tumor samples taken during surgery were used for the study. pRb expression was detected immunohistochemically using the monoclonal antibody (M7131, DAKO, Denmark) generated from mouse anti-human Rb product. The 4-μm thick sections from their original histology blocks were eparaffinized in xylene and treated with 3% hydrogen peroxide in methanol to block endogenous peroxidase. For immunohistochemical detection of the pRb protein, the sections were boiled for 30 min in 10 mmol/L citrate buffer solution (pH6.0) using a microwave heater for antigen retrieval. Mouse monoclonal anti-Rb (Clone Rb1, DAKO, Glostrup, Denmark) was used as primary antibody. The clone Rb1, which can be used on (archival) paraffin-embedded material, is a mouse monoclonal antibody against recombinant human retinoblastoma gene product representing amino acid 330-612 and reacts with the retinoblastoma gene product as indicated by immunoblotting SV40 transformed human tumor cell lines[18]. The sections were first incubated for 60 min at room temperature with the primary antibody. Biotinylated anti-mouse IgG was then applied as secondary antibody, followed by peroxidase-conjugated streptavidin. Demonstration of binding sites with the peroxidase reaction was achieved with 3, 3’-diaminobenzidine tetrahydrochloride (0.25 mg dissolved in 1 mL 0.02% hydrogen peroxide). Phosphate-buffered saline was used for rinsing between each step. Faint nuclear staining, sufficient to aid in orientation but not to influence the judgement of positivity, was performed with Mayer hematoxylin solution.

**Evaluation of pRb protein expression**

For each section, 10 high-power fields were chosen randomly, and a total of 1000 cells were evaluated by a pathologist (Tseng HH), who had no prior knowledge of the patients’ outcomes or tumor characteristics. The pattern of immunoreactivity was scored on the basis of the percentage of tumor cell nuclei with positive staining. The parameter obtained was the mean relative nuclear positive area evaluated on at least 10 fields observed at a magnification of ×40.

Immunoreactivity was semiquantitatively graded. The grade scheme was: 0+ (no immunoreactive cells present), 1+ (1%-24%), 2+ (25%-49%), 3+ (50%-74%), 4+ (75%-100%) immunoreactivity cells, respectively.

In evaluation of the clinical significance of pRb expression in gastric carcinoma, tumors with grade “0+ - 2+” immunostaining were grouped as weak staining, and tumors with grade “3+ and 4+” immunostaining as strong staining.

**Statistical analysis**

Associations between categorical variables were analyzed using Fisher’s exact test, *χ*² test, or Mann-Whitney *U* test. Univariate analysis of survival was carried out with a Kaplan-Meier estimator, and the difference between curves of subgroups was determined using the log-rank test. Survival curves were calculated by the Kaplan-Meier method and compared by the log-rank test. Independent survival variables were studied by Cox regression analysis. All data were calculated with SPSS for windows with *P* < 0.05 as the level of significance.

**RESULTS**

A total of 59 out of 91 (65%) tumors were positive for altered pRb, with 16 cases graded as “1+”, 24 as “2+”, 11 as “3+” and 8 as “4+”. In 91 unselected primary gastric carcinomas, we compared the common prognostic markers, such as age, sex, tumor location, Lauren type, tumor grading, TNM system, and altered pRb expression. On examining the distribution of tumors with strong or weak altered pRb expressions (Table 1), no significant differences were found in sex, age, tumor site, Lauren type, and histologic grading. However, statistical analysis demonstrated a significant association between altered pRb status and tumor stage. The altered pRb protein-high tumors were more in earlier stage (stages I and II) than in more advanced stage (stages III and IV) (*P* = 0.010). Moreover, the altered pRb status significantly correlated with depth of invasion (T status), but not with lymph node metastasis (N status), and distant metastasis (M status). The altered pRb expression was weak in 11 of the 17 (65%) T1 tumors, 16 of the 21 (76%) T2 tumors, 38 of the 46 (83%) T3 tumors, and 7 of the 7 (100%) T4 tumors. The altered pRb was inversely correlated with the depth of tumor invasion (*P* = 0.047).

Analysis of survival was carried out in all patients undergoing curative resection. The results of univariate analysis of survival in relation to clinicopathological findings are reported in Table 2. Tumor staging and altered pRb expression were correlated with 5-year survival. Kaplan-Meier curves showed that the 5-year survival was 80.5% in patients with strong altered pRb expression (n = 17) compared with 49.6% in patients with weak altered pRb expression (n = 58) (*P* = 0.0436). Only TNM
stage was found to be an independent prognostic factor for survival (Table 3) on multivariate analysis by Cox regression.

**DISCUSSION**

The half-life of mutant Rb protein is even longer than that of the wild Rb protein. This feature results in immunohistochemically detectable expression of the mutant Rb protein. It has been established that altered Rb protein expression pattern gives a fairly good estimate of the mutation frequency in the Rb gene.

In this study, 65% (59/91) of the tumors were positively stained and the staining in tumor nuclei of gastric carcinoma ranged 0%-90%. Constancia et al. reported that alterations affecting the Rb gene are rather infrequent in human gastric carcinomas, but our data indicate the altered pRb protein expression is frequent and widely variable in gastric carcinoma. We directly detected the altered Rb protein in tumor cells, which is different from the Constancia’s study detecting the normal Rb protein.

The Rb gene mutation is frequent in various human malignancies including sarcoma, leukemia, and esophagus, breast, bladder, prostate, and lung cancers, being similar with that in gastric carcinoma in our study.

Rb mutations resulting in the loss of Rb function play a role in the initiation of retinoblastoma and other tumors that develop as second malignancies in individuals with the hereditary form of retinoblastoma. The functional loss of the Rb gene has been implicated in a diverse group of human malignancies, including carcinoma of the breast, urinary bladder, liver, esophagus, prostate, and colon. The significance of these mutations in other tumors is a potentially critical issue. A key issue is whether the changes reported within the Rb gene in other various cancers are causally related to the initiation of tumors or whether they are involved in tumor progression. Phillips et al. reported that loss of Rb gene function is an early event in prostatic tumorigenesis. Our findings demonstrate that the altered pRb protein expression is more frequent in gastric carcinomas with superficial invasion than in those with advanced invasion. This feature means that the Rb gene mutation is also an early event in the development of gastric carcinoma and then gradually gets lost during its progression. However, only 35% (6/17) of T1 lesions had strong staining in our study. The T1 lesions occurred earlier than T2, T3, and T4 lesions and might be a “late” event in the development of gastric carcinoma. Therefore, in-depth studies should be undertaken to clarify whether the Rb gene mutation is causally related to the initiation of gastric adenocarcinoma.

---

**Table 1** Altered pRb expression and clinicopathological findings in 91 patients with gastric adenocarcinoma

| Variables                  | Altered pRb expression, n (%) |  |
|----------------------------|-------------------------------|---|
|                            | Strong | Weak |  |
| Age                        | 43     | 7 (16) | 36 (84) | 0.307 |
| < 70 yr                    | 48     | 12 (25) | 36 (75) |      |
| ≥ 70 yr                    |        |       |         |      |
| Sex                        | 80     | 17 (21) | 63 (79) | 1.000 |
| Male                       | 11     | 2 (18) | 9 (82)  |      |
| Female                     |        |       |         |      |
| Tumor location             | 18     | 2 (11) | 16 (89) | 0.553 |
| Upper third                | 19     | 5 (26) | 14 (74) |      |
| Middle third               | 54     | 12 (22) | 42 (78) |      |
| Lower third                |        |       |         |      |
| Lauren type                | 67     | 12 (18) | 55 (82) | 0.304 |
| Intestinal                 | 20     | 4 (20) | 16 (80) |      |
| Diffuse                    | 4      | 2 (50) | 2 (50)  |      |
| Mixed                      |        |       |         |      |
| Differentiation            | 49     | 10 (20) | 39 (80) | 0.905 |
| High or moderately         | 42     | 9 (21) | 33 (79) |      |
| Low                        |        |       |         |      |
| Tumor depth                | 17     | 6 (35) | 11 (65) | 0.047 |
| T1                         | 21     | 5 (24) | 16 (76) |      |
| T2                         | 46     | 8 (17) | 38 (83) |      |
| T4                         | 7      | 0 (0) | 7 (100) |      |
| Lymph node metastasis      | 28     | 9 (32) | 19 (68) | 0.109 |
| N0                         | 35     | 6 (17) | 29 (83) |      |
| N1                         | 22     | 3 (14) | 19 (86) |      |
| N2                         | 6      | 1 (17) | 5 (83)  |      |
| Distant metastasis         | 75     | 17 (23) | 58 (77) | 0.366 |
| No                         | 16     | 2 (13) | 14 (87) |      |
| Yes                        |        |       |         |      |
| TNM stage                  | 43     | 14 (33) | 29 (67) | 0.010 |
| I and II                   | 48     | 5 (10) | 43 (90) |      |
| III and IV                 |        |       |         |      |

**Table 2** Univariate analysis of survival in 75 patients with curative resection for gastric adenocarcinoma

| Variables                  | 5-year survival, n (%) | P  |
|----------------------------|------------------------|----|
| Age                        |                        |    |
| < 70 yr                    | 36 (54.0)              | 0.8036 |
| ≥ 70 yr                    | 39 (58.8)              |      |
| Sex                        |                        |    |
| Male                       | 69 (57.2)              | 0.5069 |
| Female                     | 6 (50.0)               |      |
| Tumor location             |                        |    |
| Upper third                | 14 (51.9)              | 0.4312 |
| Middle third               | 14 (64.8)              |      |
| Lower third                | 47 (54.6)              |      |
| Differentiation            |                        |    |
| Well + moderate            | 41 (66.1)              | 0.0509 |
| Low                        | 34 (42.5)              |      |
| TNM stage                  |                        |    |
| I and II                   | 43 (88.6)              | < 0.0001 |
| III and IV                 | 32 (47.4)              |      |
| Altered pRb expression     |                        |    |
| Strong                     | 17 (80.5)              | 0.0436 |
| weak                       | 58 (49.6)              |      |

**Table 3** Multivariate analysis of survival in 75 patients with curative resection for gastric adenocarcinoma

| Variables                  | Category                           | Relative risk | 95% CI  | P  |
|----------------------------|------------------------------------|---------------|---------|----|
| Histologic grade           | Poorly vs well and moderately      | 1.073         | 0.640-1.800 | 0.788 |
| Differentiated             | differentiated                     |               |         |    |
| Altered pRb expression     | Weak vs well                       | 0.891         | 0.443-1.791 | 0.746 |
| TNM stages                 |                                    |               |         |    |
| III & IV vs I & II         |                                    | 5.067         | 2.764-9.289 | 0.000 |
as in the hereditary retinoblastoma.

The prognostic value of pRb protein expression in various carcinomas has been investigated. Some studies found that pRb protein expression is an important prognostic indicator of cancers, such as bladder cancer[22] and non-small-cell lung cancer[23]. Low pRb protein expression is associated with significantly poorer survival among them. In contrast, in colorectal cancer no prognostic significance of pRb protein expression has been reported[24]. Our findings demonstrate that there is a negative correlation between pRb protein expression and survival in gastric carcinoma at univariate analysis, but not significantly correlated between them at multivariate analysis. In the present study, however, the pRb protein-high tumors were more frequent in earlier stage (stages I and II) than in advanced stage (stages III and IV), suggesting that the pRb protein expression is not an independent prognostic marker of gastric adenocarcinoma.

In conclusion, our data indicate that the mutation of Rb gene is frequent in gastric carcinoma. The expression of altered pRb protein inversely correlates with tumor invasion and is not an independent prognostic marker in gastric adenocarcinoma.

ACKNOWLEDGMENTS

The authors thank Professor Luo-Ping Ger for the statistical review and advice in the manuscript.

REFERENCES

1. Cordon-Cardo C. Mutations of cell cycle regulators. Biological and clinical implications for human neoplasia. Am J Pathol 1995; 147: 545-560
2. Weinberg RA. Tumor suppressor genes. Science 1991; 254: 1138-1146
3. Sellers WR, Kaelin WG Jr. Role of the retinoblastoma protein in the pathogenesis of human cancer. J Clin Oncol 1997; 15: 3301-3312
4. Friend SH, Bernards R, Rogelj S, Weinberg RA, Rapaport JM, Albert DM, Dyrja TP. A human DNA segment with properties of the gene that predisposes to retinoblastoma and osteosarcoma. Nature 1986; 323: 643-646
5. Fung YK, Murphee AL, T’Ang A, Qian J, Hinrichs SH, Benedict WF. Structural evidence for the authenticity of the human retinoblastoma gene. Science 1987; 236: 1657-1661
6. Lee WH, Bookstein R, Hong F, Young LJ, Shew JY, Lee EY. Human retinoblastoma susceptibility gene: cloning, identification, and sequence. Science 1987; 235: 1394-1399
7. Reissmann PT, Simon MA, Lee WH, Slamon DJ. Studies of the retinoblastoma gene in human sarcomas. Oncogene 1989; 4: 839-843
8. Hui AM, Li X, Makuuchi M, Takayama T, Kubota K. Overexpression and lack of retinoblastoma protein are associated with tumor progression and metastasis in hepatocellular carcinoma. Int J Cancer 1999; 84: 604-608
9. Furukawa Y, DeCaprio JA, Belvin M, Griffin JD. Heterogeneous expression of the product of the retinoblastoma susceptibility gene in primary human leukemia cells. Oncogene 1991; 6: 1343-1346
10. zur Hausen A, Sarbia M, Heep H, Willers R, Gabbert HE. Retinoblastoma-protein (pRB) expression and prognosis in squamous-cell carcinomas of the esophagus. Int J Cancer 1999; 84: 618-622
11. Varley JM, Armstrong J, Swallow JE, Jeffreys AJ, Pender BA, T’Ang A, Fung YK, Brammar WJ, Walker RA. The retinoblastoma gene is frequently altered leading to loss of expression in primary breast tumours. Oncogene 1989; 4: 725-729
12. Cairns P, Proctor AJ, Knowles MA. Loss of heterozygosity at the RB locus is frequent and correlates with muscle invasion in bladder carcinoma. Oncogene 1991; 6: 2305-2309
13. Bookstein R, Rio P, Madreperla SA, Hong F, Allred C, Grizzle WE, Lee WH. Promoter deletion and loss of retinoblastoma gene expression in human prostate carcinoma. Proc Natl Acad Sci USA 1990; 87: 7762-7766
14. Sakaguchi M, Fujii Y, Hirabayashi H, Yoon HE, Komoto Y, Oue T, Kusafuka T, Okada A, Matsuda H. Inversely correlated expression of p16 and Rb protein in non-small cell lung cancers: an immunohistochemical study. Int J Cancer 1996; 65: 442-445
15. Bártek J, Voitíšek B, Grand RJ, Gallimore PH, Lane DP. Cellular localization and T antigen binding of the retinoblastoma protein. Oncogene 1992; 7: 101-108
16. Geradts J, Hu SX, Lincoln CE, Benedict WF, Xu HJ. Aberrant RB gene expression in routinely processed, archival tumor tissues determined by three different anti-RB antibodies. Int J Cancer 1994; 58: 161-167
17. Xu HJ, Cairns P, Hu SX, Knowles MA, Benedict WF. Loss of RB protein expression in primary bladder cancer correlates with loss of heterozygosity at the RB locus and tumor progression. Int J Cancer 1993; 53: 781-784
18. Constanța M, Seruca R, Carneiro F, Silva F, Castedo S. Retinoblastoma gene structure and product expression in human gastric carcinomas. Br J Cancer 1994; 70: 1018-1024
19. Benedict WF, Xu HJ, Hu SX, Takahashi R. Role of the retinoblastoma gene in the initiation and progression of human cancer. J Clin Invest 1990; 85: 988-993
20. Phillips SM, Barton CM, Lee SJ, Morton DG, Wallace DM, Lemoine NR, Neoptolemos JP. Loss of the retinoblastoma susceptibility gene (RB1) is a frequent and early event in prostatic tumorigenesis. Br J Cancer 1994; 70: 1252-1257
21. Poller DN, Baxter KJ, Shepherd NA. p53 and Rb protein expression: are they prognostically useful in colorectal cancer? Br J Cancer 1997; 75: 87-93
22. Cordon-Cardo C, Warthinger D, Petrylak D, Dalbagni G, Fair WR, Fuks Z, Reuter VE. Altered expression of the retinoblastoma gene product: prognostic indicator in bladder cancer. J Natl Cancer Inst 1992; 84: 1251-1256
23. Xu HJ, Quinlan DC, Davidson AG, Hu SX, Summers CL, Li J, Benedict WF. Altered retinoblastoma protein expression and prognosis in early-stage non-small-cell lung carcinoma. J Natl Cancer Inst 1994; 86: 695-699

www.wignet.com